オメガ3処方薬の世界市場レポート 2024

オメガ3処方薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.8%の年間複合成長率（CAGR）で23億7,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、適応範囲の拡大、消費者の嗜好の変化、対象を絞った健康ソリューションの出現、個別化医療の導入、臨床証拠の拡大に関連している可能性があります。予測期間の主な動向には、パーソナライズされた健康ソリューションの台頭、対処される健康状態の拡大、革新的な製剤のイントロダクション、健康補助食品の人気の高まり、健康アプリやウェアラブルの普及が含まれます。

心血管疾患（CVD）の有病率の拡大は、オメガ3処方薬市場の拡大に大きく寄与する態勢が整っています。脂質などの物質である血中トリグリセリドのレベルの上昇は、心血管障害のリスク増加と強く相関しています。オメガ 3サプリメントは、これらの中性脂肪レベルの調節と低下に重要な役割を果たし、それによってCVDのリスクを軽減します。 2021年の世界保健機関（WHO）の報告書は、CVDによる推定死亡者数1,790万人が世界の死亡者数の32％を占めるという驚くべき統計を浮き彫りにしました。このうち心臓発作と脳卒中が原因の85％を占めました。その結果、心血管疾患の発生率の急増が、オメガ3処方薬市場の成長軌道を推進する極めて重要な推進力として浮上しています。

肥満に悩む人口の拡大は、オメガ3処方薬市場の成長に大きく貢献する態勢が整っています。体脂肪の異常または過剰な蓄積を特徴とする肥満は、個人に重大な健康リスクをもたらします。オメガ3処方薬は、肥満に関連する特定の状態を管理し、全体的な健康を増進する上で不可欠なツールとして機能し、それによって体重管理の取り組みを支援します。 2022年3月の世界保健機関（WHO）の報告書は、現在世界中で成人6億5,000万人、青少年3億4,000万人、子供3,900万人を含む10億人以上が肥満に分類されているという憂慮すべき統計を浮き彫りにしました。さらに、予測では憂慮すべき傾向が示されており、2025年までに成人と子どもを合わせて推定1億6,700万人が過体重または肥満による健康状態の悪化を経験すると予想されています。その結果、肥満と闘う人口の増加が成長の原動力として浮上しています。オメガ3処方薬市場の軌跡。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のオメガ3処方薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• バセパ
• ロバザ
• その他のタイプ
• 世界のオメガ3処方薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のオメガ3処方薬市場、用途タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 高トリグリセリド血症
• その他の用途タイプ

第7章 地域および国の分析

• 世界のオメガ3処方薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のオメガ3処方薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オメガ3処方薬市場の競合情勢
• オメガ3処方薬市場の企業プロファイル
  • Pfizer Inc.
  • BASF SE
  • Merck &Co. Inc.
  • Novartis International AG
  • Sanofi SA

第31章 その他の主要および革新的な企業

• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Intas Pharmaceuticals Ltd.
• Recordati SpA

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Omega-3 prescription drugs work by reducing triglyceride levels in the bloodstream and increasing the levels of beneficial HDL cholesterol. These essential fatty acids, derived from food or supplements, play a crucial role in nurturing a healthy body and are integral in the construction of cell walls throughout the body.

Omega-3 prescription drugs primarily comprise vascepa, lovaza, and other variants. Vascepa specifically targets reducing heart attack, stroke, and select cardiovascular conditions requiring hospitalization in adults. Approved by the FDA, Vascepa aims to mitigate the risk of specific cardiovascular issues in adults with elevated triglyceride levels and multiple additional risk factors such as hypertension, high cholesterol, or obesity. These omega-3 prescription drugs find application in managing hypertriglyceridemia and various other conditions. Their distribution channels include hospital pharmacies, retail outlets, and online pharmacies.

The omega 3 prescription drugs market research report is one of a series of new reports from The Business Research Company that provides omega 3 prescription drugs market statistics, including omega 3 prescription drugs industry global market size, regional shares, competitors with an omega 3 prescription drugs market share, detailed omega 3 prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the omega 3 prescription drugs industry. This omega 3 prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The omega 3 prescription drugs market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.63 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historical period can be credited to heightened health awareness, advancements in clinical research, a focus on cardiovascular health, medical recommendations, and improved management of chronic diseases.

The omega 3 prescription drugs market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period can be linked to the broadened scope of indications, changing consumer preferences, the emergence of targeted health solutions, the adoption of personalized medicine, and the expansion of clinical evidence. Key trends in the forecast period encompass the rise of personalized health solutions, the extension of health conditions addressed, the introduction of innovative formulations, increased popularity of health supplements, and the widespread use of health apps and wearables.

The escalating prevalence of cardiovascular diseases (CVDs) is poised to significantly contribute to the expansion of the omega-3 prescription drug market. Elevated levels of blood triglycerides, a lipid-such as substance, are strongly correlated with increased risks of cardiovascular disorders. Omega-3 supplements play a crucial role in regulating and reducing these triglyceride levels, thereby mitigating the risk of CVDs. The 2021 World Health Organization (WHO) report highlighted a staggering statistic, indicating an estimated 17.9 million fatalities attributed to CVDs, accounting for 32% of global deaths. Of these, heart attacks and strokes accounted for 85% of the causes. Consequently, the burgeoning incidence of cardiovascular diseases emerges as a pivotal driver propelling the growth trajectory of the omega-3 prescription drug market.

The expanding population grappling with obesity stands poised to significantly contribute to the growth of the omega-3 prescription drug market. Obesity, characterized by an abnormal or excessive accumulation of body fat, poses considerable health risks to individuals. Omega-3 prescription drugs serve as essential tools in managing specific conditions associated with obesity and enhancing overall health, thereby aiding in weight management endeavors. A report from the World Health Organization (WHO) in March 2022 highlighted alarming statistics, indicating that over 1 billion individuals worldwide are presently classified as obese, comprising 650 million adults, 340 million adolescents, and 39 million children. Moreover, projections indicate a troubling trend, with an estimated 167 million individuals-both adults and children-expected to experience deteriorating health due to being overweight or obese by 2025. Consequently, the escalating population grappling with obesity emerges as a driving force behind the growth trajectory of the omega-3 prescription drug market.

The omega-3 prescription drug market is witnessing a surge in the adoption of new product innovations as a prominent trend. Leading companies engaged in the manufacturing of omega-3 drugs are strategically focusing on the development of novel products to fortify their market positions. A significant milestone occurred in October 2022 when the European Commission approved plant-based omega-3 products from DSM for use as substitutes for fish and animal-derived sources across the EU. DSM asserts that these products bolster the nutritional profile of plant-based foods while facilitating the creation of fish-such as products derived from animals. This omega-3 supplement serves as a means to augment the nutritional content of various goods without adversely impacting the marine ecosystem.

Major players within the omega-3 prescription drug market are strategically concentrating on product launches, particularly capsules designed to reduce the body's production of triglycerides. Capsules, recognized as pharmaceutical or dietary supplement dosage forms, feature a shell, usually composed of gelatin or a similar substance, encapsulating a precise quantity of medication, nutrients, or other active ingredients for convenient ingestion. A notable example occurred in March 2023 when Hikma Pharmaceuticals, a multinational pharmaceutical company headquartered in England specializing in generic and in-licensed pharmaceutical products, introduced the Icosapent Ethyl Capsules, 0.5g, in the US market. This product is specifically indicated for lowering triglyceride levels in adults afflicted with severe hypertriglyceridemia, containing eicosatetraenoic acid (EPA), acknowledged for its efficacy in reducing triglycerides. This launch marks an innovation in the market, catering to the needs of addressing severe hypertriglyceridemia and meeting the escalating demand for pharmaceutical-grade omega-3 products. It aligns harmoniously with the market's heightened focus on delivering effective therapies for conditions such as elevated triglyceride levels.

In August 2021, Woodward Pharma Services, a prominent U.S.-based pharmaceutical company, successfully acquired Lovaza (omega-3-acid ethyl esters) capsules from GlaxoSmithKline for an undisclosed sum. Through this acquisition, Woodward Pharma gains the license and authority to utilize Lovaza capsules, a prescription omega-3 product approved by the FDA, specifically in adult patients with severe hypertriglyceridemia. Lovaza serves as a medical-grade supplement designed for the management of high triglyceride levels. GlaxoSmithKline, a UK-based pharmaceutical and biotechnology company, executed this strategic transaction to further strengthen Woodward Pharma's pharmaceutical offerings and market presence in the healthcare industry.

Major companies operating in the omega 3 prescription drugs market report are Pfizer Inc., BASF SE, Merck & Co. Inc., Novartis International AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Viatris Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Recordati S.p.A., Vifor Pharma Management Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Sunovion Pharmaceuticals Inc., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Amarin Pharmaceuticals Ireland Ltd., Natrapharm Inc.

North America was the largest region in the omega 3 prescription drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the omega 3 prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The omega 3 prescription drugs market consists of sales of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Omega 3 Prescription Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on omega 3 prescription drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for omega 3 prescription drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The omega 3 prescription drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Vascepa; Lovaza; Other Type
• 2) By Application Type: Hypertriglyceridemia; Other Application Type
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Companies Mentioned: Pfizer Inc.; BASF SE; Merck & Co. Inc.; Novartis International AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Omega 3 Prescription Drugs Market Characteristics

3. Omega 3 Prescription Drugs Market Trends And Strategies

4. Omega 3 Prescription Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Omega 3 Prescription Drugs Market Size and Growth

• 5.1. Global Omega 3 Prescription Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Omega 3 Prescription Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Omega 3 Prescription Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Omega 3 Prescription Drugs Market Segmentation

• 6.1. Global Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Vascepa
• Lovaza
• Other Type
• 6.2. Global Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hypertriglyceridemia
• Other Application Type

7. Omega 3 Prescription Drugs Market Regional And Country Analysis

• 7.1. Global Omega 3 Prescription Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Omega 3 Prescription Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Omega 3 Prescription Drugs Market

• 8.1. Asia-Pacific Omega 3 Prescription Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Omega 3 Prescription Drugs Market

• 9.1. China Omega 3 Prescription Drugs Market Overview
• 9.2. China Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Omega 3 Prescription Drugs Market

• 10.1. India Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Omega 3 Prescription Drugs Market

• 11.1. Japan Omega 3 Prescription Drugs Market Overview
• 11.2. Japan Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Omega 3 Prescription Drugs Market

• 12.1. Australia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Omega 3 Prescription Drugs Market

• 13.1. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Omega 3 Prescription Drugs Market

• 14.1. South Korea Omega 3 Prescription Drugs Market Overview
• 14.2. South Korea Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Omega 3 Prescription Drugs Market

• 15.1. Western Europe Omega 3 Prescription Drugs Market Overview
• 15.2. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Omega 3 Prescription Drugs Market

• 16.1. UK Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Omega 3 Prescription Drugs Market

• 17.1. Germany Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Omega 3 Prescription Drugs Market

• 18.1. France Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Omega 3 Prescription Drugs Market

• 19.1. Italy Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Omega 3 Prescription Drugs Market

• 20.1. Spain Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Omega 3 Prescription Drugs Market

• 21.1. Eastern Europe Omega 3 Prescription Drugs Market Overview
• 21.2. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Omega 3 Prescription Drugs Market

• 22.1. Russia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Omega 3 Prescription Drugs Market

• 23.1. North America Omega 3 Prescription Drugs Market Overview
• 23.2. North America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Omega 3 Prescription Drugs Market

• 24.1. USA Omega 3 Prescription Drugs Market Overview
• 24.2. USA Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Omega 3 Prescription Drugs Market

• 25.1. Canada Omega 3 Prescription Drugs Market Overview
• 25.2. Canada Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Omega 3 Prescription Drugs Market

• 26.1. South America Omega 3 Prescription Drugs Market Overview
• 26.2. South America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Omega 3 Prescription Drugs Market

• 27.1. Brazil Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Omega 3 Prescription Drugs Market

• 28.1. Middle East Omega 3 Prescription Drugs Market Overview
• 28.2. Middle East Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Omega 3 Prescription Drugs Market

• 29.1. Africa Omega 3 Prescription Drugs Market Overview
• 29.2. Africa Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Omega 3 Prescription Drugs Market, Segmentation By Application Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Omega 3 Prescription Drugs Market Competitive Landscape And Company Profiles

• 30.1. Omega 3 Prescription Drugs Market Competitive Landscape
• 30.2. Omega 3 Prescription Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. BASF SE
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis International AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi S.A.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Omega 3 Prescription Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Abbott Laboratories
• 31.3. GlaxoSmithKline plc
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Viatris Inc.
• 31.6. AbbVie Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Mylan N.V.
• 31.9. Eisai Co. Ltd.
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Cipla Limited
• 31.13. Hikma Pharmaceuticals plc
• 31.14. Intas Pharmaceuticals Ltd.
• 31.15. Recordati S.p.A.

32. Global Omega 3 Prescription Drugs Market Competitive Benchmarking

33. Global Omega 3 Prescription Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Omega 3 Prescription Drugs Market

35. Omega 3 Prescription Drugs Market Future Outlook and Potential Analysis

• 35.1 Omega 3 Prescription Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Omega 3 Prescription Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Omega 3 Prescription Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer